The company’s CLIA laboratory is processing gMSPro CDMS prognostic test that allows neurologists to predict clinical relapses in patients suspected with MS.

Glycominds has recently conducted a clinical study of gMSPro CDMS at the center for Multiple Sclerosis of Catalonia, at the University Hospital Vall d’Hebron in Barcelona Spain.

Glycominds has also developed gMSDx for early diagnosis of MS and gMSPro EDSS to predict the likelihood for rapid progression and accumulation of disabilities.

The company now plans to enter into the Japanese market.